BRCA1 and ovarian carcinoma: These results suggest that BRCA1 exon 11 mutations may not play a critical role in the oncologic outcomes of ovarian cancer compared to non-BRCA1 exon 11 mutations, but the heterogeneity in PFS warrants cautious interpretation.